Log in to search using one of your social media accounts:

 

Impact of chemotherapy-induced neurotoxicities on adult cancer survivors ’ symptom burden and quality of life

AbstractPurposeLimited information is available on the impact of chemotherapy (CTX)-induced neurotoxicity on adult survivors ’ symptom experience and quality of life (QOL). Purposes were to describe occurrence of hearing loss and tinnitus and evaluate for differences in phenotypic characteristics and measures of sensation, balance, perceived stress, symptom burden, and QOL between survivors who received neurotoxic CTX a nd did (i.e., neurotoxicity group) and did not (i.e., no neurotoxicity group) develop neurotoxicity. Neurotoxicity was defined as the presence of chemotherapy-induced neuropathy (CIN), hearing loss, and tinnitus. Survivors in the no neurotoxicity group had none of these conditions.MethodsSurvivors (n = 609) completed questionnaires that evaluated hearing loss, tinnitus, stress, symptoms, and QOL. Objective measures of sensation and balance were evaluated.ResultsOf the 609 survivors evaluated, 68.6% did and 31.4% did not have CIN. Of the survivors without CIN, 42.4% reported either hearing loss and/or tinnitus and 48.1% of the survivors with CIN reported some form of ototoxicity. Compared to the no neurotoxicity group (n = 110), survivors in the neurotoxicity group (n = 85) were older, were less likely to be employed, had a higher comorbidity burden, and a higher symptom burden, higher levels of perceived stress, and poorer QOL (allp 
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research

Related Links:

The most common adverse effects from neurotoxic chemotherapy are chemotherapy-induced neuropathy (CIPN), hearing loss, and tinnitus. While associations between perceived stress and persistent pain, hearing loss, and tinnitus are documented, no studies have examined these associations in cancer survivors who received neurotoxic chemotherapy.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Tags: LETTER TO THE EDITOR Source Type: research
Conclusions: The results are testament to benefits of routine audiometric monitoring program during cisplatin-based chemotherapy. Further research should be performed to understand other risk factors, such as genetic predictors of Cisplatin-induced ototoxicity. PMID: 28441710 [PubMed - as supplied by publisher]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
CONCLUSION: Long-term MOGCT survivors treated with CBCT have small but significant reductions in age-adjusted hearing thresholds at 4, 6 and 8kHz versus Controls. Approximately one in four women experienced subjective hearing loss. To avoid overestimation of clinically relevant cisplatin-induced ototoxicity, absolute hearing thresholds should be age-adjusted and compared to an age-matched control group. PMID: 28202195 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
ConclusionsOur data show that the burden of hearing loss has stabilized in recently treated survivors, suggesting that survivors have benefited from new treatment regimens that use less ototoxic radiation and more carefully dosed platinum compounds.
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
Haugnes HS Abstract OBJECTIVE: To evaluate the associations between long-term serum levels of platinum (se-Pt) and neurotoxicity and ototoxicity (NTX), endocrine gonadal function (endocrine-GF), and cardiovascular disease (CVD) in testicular cancer survivors. MATERIAL AND METHODS: A total of 292 cisplatin-treated testicular cancer survivors (1980-1994) participated in a national follow-up study (2007-2008). Se-Pt was quantified by inductively coupled plasma mass spectrometry, and categorized in quartiles. Symptoms of NTX were assessed with scale for chemotherapy-induced neurotoxicity (SCIN), with each symptom...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
Purpose Cisplatin is widely used but highly ototoxic. Effects of cumulative cisplatin dose on hearing loss have not been comprehensively evaluated in survivors of adult-onset cancer. Patients and Methods Comprehensive audiological measures were conducted on 488 North American male germ cell tumor (GCT) survivors in relation to cumulative cisplatin dose, including audiograms (0.25 to 12 kHz), tests of middle ear function, and tinnitus. American Speech-Language-Hearing Association criteria defined hearing loss severity. The geometric mean of hearing thresholds (0.25 to 12 kHz) summarized overall hearing status consistent wi...
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Chemotherapy, Outcomes Research Treatment-Related Complications Source Type: research
Conclusions Cancer treatment causes hearing loss, associated with the administration of chemotherapy and radiotherapy. Cyclophosphamide increased the risk of causing hearing loss. Complaints of tinnitus and speech understanding difficulty were observed.
Source: Brazilian Journal of Otorhinolaryngology - Category: ENT & OMF Source Type: research
Conclusions Cancer treatment causes hearing loss, associated with the administration of chemotherapy and radiotherapy. Cyclophosphamide increased the risk of causing hearing loss. Complaints of tinnitus and speech understanding difficulty were observed.
Source: Brazilian Journal of Otorhinolaryngology - Category: ENT & OMF Source Type: research
OBJECTIVE: To describe a case of metastatic seminoma-associated multi-phasic meningoencephalomyeloradiculopathy lacking Ma2 or other definable autoantibodies. BACKGROUND: Paraneoplastic disorders with testicular cancers are often associated with Ma2 autoantibody. Neurological symptoms can precede cancer diagnosis. Treatment consists of tumor removal and immunotherapy. DESIGN/METHODS/RESULTS: A 29 year-old man with well-controlled ulcerative colitis (onset age 10) presented elsewhere with subacute tinnitus, hearing loss, diplopia and imbalance. There were enhancing T2/FLAIR hyperintensities in the brainstem and bilateral th...
Source: Neurology - Category: Neurology Authors: Tags: MS and CNS Inflammatory Diseases: CNS Inflammatory Diseases and Differential Diagnosis Source Type: research
More News: Audiology | Brain | Cancer | Cancer & Oncology | Chemotherapy | Neurology | Tinnitus